Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.38%
#2 Victoria VR Victoria VR +11.93%
#3 Movement Movement +11.39%
#4 Palladium Network Palladium Network +9.28%
#5 DMT-NAT DMT-NAT +6.25%
#6 Cryptopia Cryptopia +4.73%
#7 Pons Pons +4.23%
#8 GRVT Token GRVT Token +3.85%
#9 MarsCoin MarsCoin +3.69%
#10 COTI COTI +3.65%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Ember Therapeutics, Inc. Ember Therapeutics, Inc.

Ember Therapeutics, Inc.

EMBT
Rank in Stocks #42686
Ember Therapeutics, Inc. operates as a biopharmaceutical company currently in... Ember Therapeutics, Inc. operates as a biopharmaceutical company currently in its clinical development phase. Its core mission involves exploring the therapeutic applications of bone morphogenetic protein-7 (BMP-7) to engineer regenerative treatments. These innovative therapies are designed to alter the course of osteoarthritis, reverse insulin resistance, and inhibit or undo organ fibrosis in diseases such as chronic kidney disease and Alport's syndrome, alongside metabolic conditions like obesity and type 2 diabetes. Among its leading BMP-7-based drug candidates, MT-006 has successfully completed a Phase 2a clinical trial focused on osteoarthritis. Furthermore, MT-007, aimed at CKD and Alport syndrome; MT-008, specifically for Alport syndrome; and MT-009, targeting metabolic disease, have all concluded their preclinical trial phases. The company also maintains a substantial intellectual property portfolio, encompassing approximately 450 patents related to BMP-7, its associated protein families, various derivatives, novel delivery systems, specialized formulations, supporting clinical data, and materials produced under current good manufacturing practices. Ember Therapeutics, Inc. was established in 2010 and is headquartered in New York, New York.
Share Price
$0.0001
Last synced: 2026-02-06
Market Cap
$398.00
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Ember Therapeutics, Inc. (EMBT)

Category

Healthcare
Revenue for Ember Therapeutics, Inc. (EMBT)
Revenue in Aug 2026 TTM: 0
According to Ember Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Ember Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE